News About: Pharm. Industry
Febuxostat acquires the 13th exclusive sale product right
‘Febuxostat,’ which has been prohibited to sell due to the lawsuit winning of generic companies, was registered as the 13th exclusive sales pharmaceutical product.
The Ministry of Food and Drug Safety(MFDS) announced...
Less sales positions lead to more researchers in pharmaceutical employment
Among various job positions in the pharmaceutical industry, sales positions are observed to decrease while researchers increased for the past 10 years.
Considering other job positions have similar ratios compared wit...
Amendment to the Pharmacist Affairs Law passed the general meeting
At the last general meeting of the 19th National Assembly, the amendments to the Pharmacist Affairs Law and the Medical Law, which includes revisions such as the DUR Enactment and the CSO Rebate Prohibition, passed th...
Cialis launches counterattack against 21 domestic companies, filing appeal to Patent Court
Cialis, which has encountered the crisis of its generic products, is getting ready to launch a counterattack.
The company filed an appeal against the 21 companies at the Patent Court as protesting the Intellectual Pr...
Pharmaceutical industry expect next year’s market condition conservatively, setting target growth rates at 5-10%
Most pharmaceutical companies foresaw the next year’s pharmaceutical economy is unclear even worse than this year, and set their growth goal at 5% to 10%.
According to the industry concerned on the 9th, pharmaceutica...
Ilyang Pharm advances to the global market with leukemia treatment, ‘Supect’Ilyang Pharm(CEO Dong-yun Kim) attracted interest of the global market as announcing 3 results of the final clinical trial of the Asia’s first leukemia treatment, ‘Supect(generi...
|
This year’s pharmaceutical sales records KRW 12.6 trillion increasing 3.4% up
This year, pharmaceutical sales were forecasted to increase 3.4% up over the last year and record KRW 12.6 trillion.
Shinhan Investment Corp., recently, forecasted pharmaceutical sales will be KRW 12.6 trillion and p...
Yuhan tops KRW 1.1 trillion, Green Cross and Hanmi are likely to achieve KRW 1 Trillion Club
The top pharmaceutical trios of the year are most likely to achieve the 1 Trillion Club. Yuhan Corporation, which exceed KRW 1 trillion sales for the first time, is sure to record KRW 1.1 trillion keeping the upturn.
...
Samsung Bioepis acquires domestic product approval of ‘Renflexis’
Samsung Bioepis announced acquisition of product approval of Renflexis(Remicade biosimilar), an autoimmune disease treatment, from the Ministry of Food and Drug Safety on the 4th.
Thus, Samsung Bioepis has become a c...
Novartis informs Early Retirement Program to layoff staffs in 2 yearsNovartis Korea will start the Early Retirement Program(ERP).
According to the industry concerned, Novartis has suggested target departments and conditions with the ERP announce...
|
